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Endothelial dysfunction is found in hypertensive patients and may serve as a prognostic marker of future cardiovascular events.
Endothelial function can be assessed noninvasively by ﬂow-mediated vasodilation (FMD). The goal of this paper is to summarize
comprehensively the clinical trials that investigated the eﬀects of antihypertensive drugs on endothelial function assessed by
FMD in hypertensive patients. A PubMed-based search found 38 clinical trial papers published from January 1999 to June 2011.
Signiﬁcant improvement of FMD after antihypertensive treatment was shown in 43 of 71 interventions (among 38 clinical trial
papers). Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors appeared to improve FMD more than
other drug types. Antihypertensive treatment can improve endothelial dysfunction when assessed by FMD, although there are
conﬂicting data that require further research.
1.Introduction
Atherosclerotic risk factors such as hypertension (HTN),
diabetes mellitus, dyslipidemia, obesity, and smoking cause
endothelial dysfunction [1–5]. Endothelial dysfunction
occurs in the early stages of atherosclerosis and is involved
in disease progression as well as the morbid cardiovascular
events that often occur in advanced stages of the diseases
[1–5]. The endothelium is involved in the control of the
coagulation/ﬁbrinolytic system, platelet aggregation, adhe-
sion of leukocytes, and smooth muscle cell proliferation and
is important in the maintenance of vascular tone [1, 3].
The response-to-injury hypothesis, proposed by Russell Ross
[6], states that atherosclerosis is due to an inﬂammatory
reaction in response to endothelial injury or dysfunction and
is supported by numerous basic and clinical investigations
[1, 3].
The evaluation of endothelial function is available as
a predictor of cardiovascular events and as a surrogate
marker for early atherosclerosis [1–3, 7, 8]. There are several
methods to evaluate endothelial function that include an
invasive method using endothelium-dependent vasodilators
injected into a coronary or peripheral artery [7], and ﬂow-
mediated vasodilation (FMD), a noninvasive method based
on endothelium-dependent arterial vasodilation [9, 10].
FMD was ﬁrst reported in 1992 by Celermajer et al., as an
innovativemethodofdetectingendothelialdysfunction[10].
The sudden release of an artery after transient occlusion
causes an increase in shear stress on the vessel wall due to
hyperemia and this stimulates endothelial cells to release
various physiologically active substances. Nitric oxide (NO)
is one of the main substances released by the endothelium
and causes relaxation of vascular smooth muscle with
a subsequent increase in vascular diameter [1]. FMD is
measuredfromtheexpansionrateofarterialdiameterduring
the postischemic hyperemia response. Since guidelines for
the measurement of FMD have been established [9] and the
measuring equipment has been improved, FMD is gaining
acceptance as a simple, safe, and valuable method to evaluate
endothelial function in clinical practice.
HTN is prevalent worldwide and one of the most
important risk factors for atherosclerotic disease [11, 12].
The relationship between FMD and blood pressure has
been reported in a general population [13, 14]. FMD was2 International Journal of Vascular Medicine
inversely related to age, male gender, systolic blood pressure,
body mass index, and smoking in the Framingham study
[13]. It was inversely correlated with male gender, blood
pressure, glucose, and directly with high-density lipoprotein
cholesterol, C-reactive protein, and body mass index in
healthy young adults (Young Finns study) [14]. Moreover,
treatment of HTN leads to the prevention of atherosclerotic
disease [11, 12] .T h e r ea r es e v e r a lt y p e so fa n t i h y p e r t e n s i v e
drugs used to treat HTN, and several studies investigated the
eﬀect of antihypertensive medications on FMD. It is possible
that the choice of the best drug to treat HTN in the future
could be based on the magnitude of the improvement in
endothelial function. This paper comprehensively summa-
rizes the current knowledge from the clinical trials that have
evaluated the eﬀect of antihypertensive drugs on FMD in
patients with HTN.
2.Methodology ofFMD
Guidelines for the ultrasound assessment of endothelial-
dependent FMD of the brachial artery have been established
[9]. There are still some issues with the reproducibility and
objectivity of FMD measurements, because it is necessary to
recordverysmallchangesinvasculardiameter[9],andsono-
graphers must receive adequate training and gain experience
before they become competent with this technique. Subjects
should fast for at least 8 to 12 hours before the measurement.
In addition, subjects should not exercise, should not ingest
substances that might aﬀect FMD, such as caﬀeine, or use
tobacco for at least 4 to 6 hours before the measurement.
FMD is assessed in a subject’s right arm in the supine
position in a quiet, temperature-controlled room. The
brachial artery is imaged above the antecubital fossa in
the longitudinal plane using B-mode ultrasound, and the
diameter of the brachial artery is measured continuously.
Ac u ﬀ is placed either around the forearm or above the
antecubital fossa. After a baseline, resting image is acquired,
arterial occlusion is induced by cuﬀ inﬂation to a pressure
above the systolic pressure, typically to at least 50mmHg
above systolic pressure for 5 minutes. When the cuﬀ is
released,FMDiscalculatedasthemaximumpercentincrease
in the diameter during hyperemia compared with the
baseline diameter.
3.ClinicalTrialsUsing FMD
Several studies were reviewed that investigated changes
in FMD due to treatment in hypertensive patients. We
selected 38 papers published from January 1999 to June
2011 using a PubMed-based search engine. The keywords
used in the search were “ﬂow-mediated vasodilation” and
“hypertension”, and the original articles were eligible. The
appropriateness of all papers identiﬁed by the search was
conﬁrmed by two experts. When the trial designs of 38
clinical trial papers were classiﬁed by the method of Zaza et
al. [15], there were 26 randomized controlled trials (RCTs),
5 controlled clinical trials (CCTs), and 7 single-arm trials
that were selected (Table 1). The comparisons of multiple
antihypertensive drugs were usually done in RCTs or CCTs,
and 71 interventions with each antihypertensive drug were
investigated in these 38 clinical trial papers. Signiﬁcant
improvement of FMD after antihypertensive treatment was
shown in 43 of 71 interventions.
Medications that block the renin-angiotensin-
aldosterone system (RAAS) include angiotensin converting
enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs). These agents are eﬀective in lowering blood
pressure and result in organ protection that is eﬀective for
clinical conditions such as heart failure [12, 54], chronic
kidney disease [12, 55], and diabetes mellitus [12, 56]. As
shown in Table 1, most studies have shown that ARBs and
ACEIs could improve FMD. One RCT compared the eﬀects
of the ACEI enalapril (5–40mg/day, n = 9) and the ARB
losartan (50–100mg/day, n = 9) on endothelial function
in hypertensive patients [17]. Six months after treatment,
FMD improved in both treatment groups compared with
baseline levels. In another RCT, patients with HTN were
given one of three diﬀerent ARBs (losartan 50–100mg/day,
n = 31; irbesartan 150–300mg/day, n = 30; candesartan
8–16mg/day, n = 31) for 2 months, and the change in
FMD was compared among the three groups. ARB therapy
signiﬁcantly improved FMD with no diﬀerences among the
three groups [23]. The other RCT (cross-over design) also
investigated the improvement of FMD during 3 months
of treatment with a low or a high dose of ramipril (5 or
10mg/day, n = 46) [28]. While both dosages of ramipril
increased FMD, the increase of NO-dependent FMD using
NG-monomethyl-L-arginine to block NO synthase was
greater with the high than with the low dose [28]. In another
RCT, treatment with the calcium channel blocker (CCB)
amlodipine (5mg/day, n = 22) did not change FMD as
much as treatment with the ARB telmisartan (40mg/day,
n = 21) for 24 weeks [24]. There were other similar RCTs
that compared ACEIs or ARBs with CCBs (perindopril
versus amlodipine [34], valsartan versus amlodipine [50],
and olmesartan versus amlodipine [52]), and all of these
trials showed that ARBs or ACEIs signiﬁcantly improved
FMD compared with CCBs.
T h ep r o t e c t i v ee ﬀect of CCBs on cardiovascular disease
in hypertensive patients has been established in several large-
scale clinical trials [12, 57]. However, RCTs which showed
improvement of FMD were limited [16, 21, 24, 26, 31, 33, 34,
50, 52].
β-blockers have also an established role in cardioprotec-
tion [12, 54, 58]. Among various β-blockers, nebivolol is
a selective β-1 adrenergic receptor antagonist and induces
endothelial-dependent vasodilation [59]. One RCT com-
pared the eﬀect of nebivolol (5mg/day, n = 20) with
atenolol (100mg/day, n = 20), a traditional selective β-1
adrenergic receptor blocker without vasodilating properties,
on FMD in hypertensive patients [41]. At 4 weeks after
treatment, FMD improved more with nebivolol than with
atenolol. Furthermore, there were several trials that showed
improvement of FMD by nebivolol compared with baseline
[36,43];however,thisdrughadlessofaneﬀectonFMDthan
other drug types.
Several RCTs compared three or more types of antihy-
pertensive drugs [21, 23, 25, 29, 49]. One RCT investigatedInternational Journal of Vascular Medicine 3
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Figure 1: Columns indicate the number of clinical trials that
showed the presence or the absence of signiﬁcant improvement of
ﬂow-mediated vasodilation from baseline due to the intervention.
FMD: ﬂow-mediated vasodilation; ARBs: Angiotensin II receptor
blockers; ACEIs: Angiotensin converting enzyme inhibitors; CCBs:
Calcium channel blockers.
the eﬀects of the ACEI perindopril (2–4mg/day, n = 28),
the ARB telmisartan (80–160mg/day, n = 29), the CCB,
nifedipine (30–60mg/day, n = 28), the CCB amlodipine (5–
10mg/day, n = 28), the β-blocker atenolol (50–100mg/day,
n = 29), and the β-blocker nebivolol (5–10mg/day, n = 28)
on FMD [21]. Interestingly, only perindopril signiﬁcantly
improvedFMD,whereasallthedrugsreducedbloodpressure
to similar levels.
Furthermore, there was one study that examined the
signiﬁcanceofFMDasaprognosticmarkerofcardiovascular
events. Postmenopausal women (n = 400) with HTN
and impaired FMD received 6 months of antihypertensive
therapy (the choice of the antihypertensive drug used was
at the discretion of the study investigators) and then were
followed-up for a mean period of 67 months. After 6 months
of treatment, 250 women showed signiﬁcantly improved
FMD, and this group had signiﬁcantly fewer cardiovascular
events compared with the group without improved FMD
(there were no deaths from cardiac causes during the study
period) [8].
A prospective study showed the relationship between
a low level of FMD and cardiovascular events (although
this study did not necessarily have an intervention) [60].
Hypertensive patients (n = 172) were divided into a low-
and high-FMD group based on the median level of FMD
and were followed for 95 months [60]. The incidence of
cardiovasculareventswas1.4and3.1per100patient-yearsin
the low and high groups, respectively. In a Cox proportional
hazards analysis, the low-FMD group showed a 2.67-fold
increased risk of cardiovascular events [60].
Given the overall data, antihypertensive treatment can
improveendothelialdysfunctionwhenassessedbyFMD.The
results of clinical trials showing the eﬀects of diﬀerent drug
t y p e so nc h a n g ei nF M Da r es u m m a r i z e di nFigure 1.M o r e
interventions that showed signiﬁcant improvement of FMD
appeared to be found in patients treated with ARBs and
ACEIs than those treated with other drug types. However,
this is not conclusive, because there has been no single RCT
that compared the eﬀects of all drug types on FMD.
Although discrepant results among trials remain to be
resolved, they may have been due to diﬀerences in the
characteristics of patients, the experimental design (i.e.,
cross-over or parallel group, and the duration of treatment
in the intervention), the sample size (relating to the study
power) and statistical methodology, and measurement issues
(e.g., reproducibility of FMD) [61–63] .Ap r e v i o u ss t u d y
demonstrated that the coeﬃcients of variation of FMD
ranged from 6.6 to 10.6% in healthy adults that underwent
repeated FMD at intervals of up to 3 months (n = 42,
meanage =43)[61].Patientswithatheroscleroticriskfactors
can also show decreased reproducibility of FMD due to the
progression of atherosclerosis over time (e.g., with structural
and functional changes of arteries) [62, 63].
4. Mechanisms of the Improvement of FMD
Endothelial dysfunction is generally caused by a reduction
of endothelium-derived relaxing factors (EDRFs) such as
NO, failure of smooth muscle cells to respond to EDRF,
activation of the RAAS, and production of vasoconstrictors
such as endothelin [1–5]. These factors are also inﬂuenced
by vascular inﬂammation associated with oxidative stress [1–
5]. However, damaged endothelial cells can be replicated
locallyanddevelopintomatureendothelialcellswithnormal
function [1, 64, 65]. Circulating endothelial progenitor
cells from bone marrow also participate in the repair of
the endothelium [1, 64]. The balance between endothelial
impairment and repair is a major determinant of endothelial
function. Of note, there have been trials that measured
biochemical markers such as NO, oxidative stress, and
inﬂammatory markers, in addition to FMD [17, 18, 22,
23, 27, 29, 31, 32, 35, 37, 38, 41, 43, 44, 46, 49, 51–53].
One RCT compared the CCB azelnidipine (16mg/day) with
the CCB benidipine (4mg/day) in a cross-over design with
8 weeks on each drug [37]. That study examined serum
levels of NO and malonyldialdehyde low-density lipoprotein
(MDA-LDL) and found that there was no diﬀerence in
FMD or the levels of NO and MDA-LDL between the
two drugs. Another cross-over RCT (n = 13, 4 weeks on
each drug) compared the eﬀects of losartan (100mg/day)
and atenolol (100mg/day) on FMD and the levels of 8-
isoprostane, a marker of oxidative stress [32]. Losartan, but
not atenolol, signiﬁcantly improved FMD and reduced 8-
isoprostane levels [32]. In hypertensive patients treated with
zofenopril (15–30mg/day, n = 15), ramipril (2.5–5mg/day,
n = 15), or atenolol (50–100mg/day, n = 15) for 8 weeks,
therewasasimilarimprovementinFMD,butonlyzofenopril
signiﬁcantlyreducedplasmahydroperoxides,8-isoprostanes,
oxidized-LDL, and adhesion molecules [29]. Other trials
have shown that NO, oxidative stress, and inﬂammatory
markers can change in parallel with changes in FMD [17, 18,
22, 23, 27, 29, 32, 35, 38, 41, 43, 46, 51, 52].
Angiotensin II causes vasoconstriction and increases the
production of reactive oxygen species (ROS) by activating
NADH/NADPH oxidase through the angiotensin II type 1
receptor [66, 67]. ARBs speciﬁcally bind to the angiotensin II
type 1 receptor and inhibit vasoconstriction, ﬂuid retention,
and sympathetic nerve activity by blocking the eﬀects of8 International Journal of Vascular Medicine
angiotensin II [68, 69]. Furthermore, ARBs promote the
activation of the angiotensin II type 2 receptor involved in
NO production [70]. ARBs also decrease oxidative stress
within the vessel wall by reducing the production of ROS
and increasing NO production, which leads to improved
endothelial function.
ACEIs block the RAAS and augment prostaglandins
and the kallikrein-kinin system, and these eﬀects lead to
a decrease in blood pressure [68, 69]. ACEIs also activate
NO production through suppression of the degradation of
bradykinin [68, 69]. Whereas ACEIs are diﬀerent from ARBs
in their site of action, both drugs have a common action to
inhibit the eﬀects of angiotensin II [68, 69], and most studies
showed that these two drug types improved endothelial
function.
CCBs have antihypertensive eﬀects that are mediated
through the relaxation of vascular smooth muscle cells, and
antioxidative eﬀects that are mediated through an increased
release of NO [71, 72].
β-blockers have scavenging activity for ROS, and these
eﬀects are possibly useful in preventing oxidative damage in
HTN[73].However,theimprovementofFMDbyβ-blockers
was not as great as that observed with other antihypertensive
agents. Nebivolol, which is associated with NO-induced
vasodilation,improvedendothelialfunctionmorethanother
β-blockers.
Atherosclerotic risk factors such as diabetes mellitus
and dyslipidemia also aﬀect endothelial function, similar
to HTN. These risk factors are often observed in patients
with HTN. While the eﬀects of these risk factors on FMD
shouldbeconsidered,speciﬁctrialsforpatientswithdiabetes
mellitus or dyslipidemia were not included among the
studies cited in the present paper.
5.PerspectiveofResearch on FMD inHTN
HTN is a major atherosclerotic risk factor, and antihyperten-
sive treatment protects against future cardiovascular events.
The evaluation of endothelial function can be useful in
the risk assessment of hypertensive patients treated with
antihypertensive drugs. However, larger clinical trials that
include morbidity and mortality as outcome variables are
needed to further establish FMD as a prognostic marker in
hypertensive patients. The inﬂuence of other atherosclerotic
risk factors and confounding factors (such as obesity,
diabetes, cigarette smoking, and dyslipidemia) on FMD in
hypertensive patients should also be evaluated in future
studies that attempt to establish the prognostic value of
FMD. Furthermore, future studies should examine the
association between the reduction in blood pressure and
the improvement in FMD. In addition, changes in FMD
should be compared with sonographical ﬁndings of carotid
arteries, ankle brachial index, and pulse wave velocity, which
have already been widely adopted as noninvasive methods to
evaluate atherosclerosis.
6. Conclusions
The improvement of FMD in hypertensive patients is
expected to slow the progression of atherosclerosis and
improve long-term outcomes in these patients. The results
of many but not all clinical trials suggest that there is a
signiﬁcant eﬀect of antihypertensive therapy on FMD. ARBs
and ACEIs appeared to improve FMD relative to other drug
types. Antihypertensive treatment can generally improve
endothelial dysfunction as assessed by FMD, although fur-
ther research is needed.
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